We leverage the potential of immunotherapy to create and provide groundbreaking treatments for cardiovascular diseases. 

Polygon is pioneering the emerging field of cardio-immunology by exploring the dynamic interplay between the immune system and cardiovascular well-being.

Our research has unveiled the pivotal role played by immune cells in the initiation and progression of cardiovascular conditions.

Discover our 1st program EMOTION: Exploration and MOdulation of CD8+ T cells in myocardial infarction.

We showed that CD8+ T cells have a pathogenic role in acute myocardial infarction (Santos et al, Nature Communications, 2021).

Our PoC shows that targeting CD8+T cells in acute MI is highly protective in-vitro and in-vivo.

We have developed PLG-101, the first human
anti-CD8 monoclonal antibody.

PLG-101 successfully cleared all NONclinical steps.

PLG-101 has demonstrated in in vivo models its capacity to reduce the infarct size by 60% and improve the heart function by 25% without any side effect.

PLG-101 is an anti-CD8 monoclonal antibody administered in one single injection during the reperfusion procedure.